Clinical Trial Research

ImmunoVaccine Technologies Discusses Phase I Clinical Trial Application

Published in Vaccine Weekly, February 6th, 2008

ImmunoVaccine Technologies Inc. (IVT) announced that it has met with Health Canada's regulatory affairs division, the Biologics and Genetic Therapies Directorate, to discuss requirements for a Phase I clinical trial application. For Phase I human clinical trials, IVT plans to combine novel antigens with its vaccine-enhancement technology, the VacciMax(R) platform.

"We are seeing impressive pre-clinical results with the VacciMax(R) platform," said Dr. Randal Chase, president and CEO of IVT. "The comments from the Biologics and Genetic Therapies Directorate are much appreciated because they give us direction as we proceed with our clinical development in Canada," said Dr....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2008-02-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry